Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: A children's oncology group phase I consortium study

Journal of Clinical Oncology

Volumn 26, Issue 30, 2008, Pages 4921-4927

  Jakacki, Regina I ^a   Hamilton, Marta ^a   Gilbertson, Richard J ^a   Blaney, Susan M ^a   Tersak, Jean ^a   Krailo, Mark D ^a   Ingle, Ashish M ^a   Voss, Stephan D ^a   Dancey, Janet E ^a   Adamson, Peter C ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; BETA CYCLODEXTRIN SULFOBUTYL ETHER; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ORA SWEET; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; QUINAZOLINE DERIVATIVE;

ACNE; ADOLESCENT; ADULT; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DOSE CALCULATION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; EPENDYMOMA; FATIGUE; FEMALE; GERM CELL TUMOR; GLIOBLASTOMA; GLIOSIS; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MORNING DOSAGE; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; NEUROBLASTOMA; NEUTROPENIA; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RASH; RECOMMENDED DRUG DOSE; RHABDOID TUMOR; RHABDOMYOSARCOMA; SIDE EFFECT; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMATITIS; TABLET FORMULATION; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; TUMOR RECURRENCE; VOMITING; AREA UNDER THE CURVE; BONE TUMOR; BRAIN TUMOR; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG ERUPTION; NEOPLASM; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BONE NEOPLASMS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DIARRHEA; DRUG ERUPTIONS; HUMANS; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; NEUROBLASTOMA; OSTEOSARCOMA; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RHABDOMYOSARCOMA;

EID: 54449085941     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.2306     Document Type: Article

References (30)

1. Bredel M, Pollack IF, Hamilton RL, et al: Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 5:1786-1792, 1999
2. Zhang L, Jope RS: Muscarinic M3 and epidermal growth factor receptors activate mutually inhibitory signaling cascades in human neuroblastoma SH-SY5Y cells. Biochem Biophys Res Comm 255:774-777, 1999
3. De Giovanni C, Landuzzi L, Frabetti F, et al: Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells. Cancer Res 56:3898-3901, 1996
4. Gilbertson RJ: ERBB2 in pediatric cancer: Innocent until proven guilty. Oncologist 10:508-517, 2005
5. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250, 1999
6. Raben D, Helfrich B, Chan DC, et al: The effects of cetuximab alone and in conjunction with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 11:795-805, 2005
7. Ciardiello F, Caputo R, Bianco R, et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinas inhibitor. Clin Cancer Res 6:2053-2063, 2000
8. Moyer JD, Barbacci EG, Iwata KK, et al: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838-4848, 1997
9. Schaefer G, Shao L, Totpal K, et al: Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res 67:1228-1238, 2007
10. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899, 2005
11. Krempien R, Muenter MW, Huber PE, et al: Randomized phase II study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer: PARC - Study protocol [ISRCTN56652283]. BMC Cancer 5:131, 2005
12. Higgins B, Kolinsky K, Smith M, et al: Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 15:503-512, 2004
13. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
14. Friedman HS, Dolan ME, Pegg AE, et al: Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 55:2853-2857, 1995
15. Middlemas DS, Stewart CF, Kirstein MN, et al: Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 6:998-1007, 2000
16. Vassal G, Terrier-Lacombe MJ, Willington MA, et al: Antitumor activity of temozolomide in relation to DNA repair activity in neuroblastoma. Proc Am Assoc Cancer Res 42:324, 2001 (abstr)
17. Rubie H, Chisholm J, DeFachelles AS, et al: Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: A joint Societe Francaise des Cancers de l'enfant and United Kingdom Children Cancer Study Group New Agents Group study. J Clin Oncol 24:5259-5264, 2006
18. Nicholson HS, Kretschmar CS, Krailo M, et al: Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: A report from the Children's Oncology Group. Cancer 110:1542-1550, 2007
19. Hwang E, Rich JN, Friedman HS, et al: Antitumor activity of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with temozolomide in human cancer xenografts. Proc Am Assoc Cancer Res 43:787-788, 2002
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
21. Gnekow AK: Recommendations of the Brain Tumor Subcommittee for the Reporting of Trials: SIOP Brain Tumor Subcommittee - International Society of Pediatric Oncology. Med Pediatr Oncol 24:104-108, 1995
22. Ling J, Johnson KA, Miao Z, et al: Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 34:420-426, 2006
23. Calabrese C, Poppleton H, Kocak M, et al: A perivascular niche for brain tumor stem cells. Cancer Cell 11:69-82, 2007
24. Wen Y, Hu M, Makino K, et al: HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the AKT pathway. Cancer Res 60:6841-6845, 2000
25. Hidalgo M, Siu LL, Nemaunatis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
26. Lu JF, Eppler SM, Wolf J, et al: Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationships in patients with non-small cell lung cancer. Clin Pharmacol Ther 80:136-145, 2006
27. Wacker B, Nagrani T, Weinberg J, et al: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913-3921, 2007
28. α-1 Acid Glycoprotein [Package Insert V4]. Indianapolis, IN, Roche Diagnostics Corporation, 2003-2006
29. Abbas R, Fettner S, Riek M, et al: A drug-drug interaction to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, erlotinib, in healthy subjects. Proc Am Soc Clin Oncol 22:137, 2003 (abstr 548)
30. Prados MD, Lamborn KR, Chang S, et al: Phase I study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-Oncol 8:67-78, 2006